Preimplantation genetic diagnosis (PGD) Market by Test Type and Geography - Global Opportunity Analysis and Industry Forecast, 2014-2022

Preimplantation genetic diagnosis (PGD) Market by Test Type and Geography - Global Opportunity Analysis and Industry Forecast, 2014-2022

Category : Diagnostic and Biotech
Published On : December  2016
Pages : 100



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Preimplantation genetic diagnosis (PGD) also referred as embryo screening, is a branch of genetics involves in genetic testing of embryo through in-vitro fertilization (IVF). PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders such as spinal muscular atrophy and cystic fibrosis.

The global PGD market size is estimated to be $79.5 million in 2015 and expected to reach $121.5 million registering a CAGR of 6.14% from 2016 to 2022. The global PGD market is expected to witness notable growth in the near future owing to the rise in prevalence of genetic, hereditary, and chromosomal diseases. Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the market growth. Moreover, stringent government regulations and ethical concerns also obstruct the market growth. In the near future, increase is expected in adoption of PGD worldwide owing to its various applications for development of healthy embryo.

The global PGD market is segmented based on the test type and geography. Based on type, the market can be segmented into aneuploidy, chromosomal abnormalities, gender selection, HLA typing, single gene disorder, X-linked diseases, and others (disability, and adult onset disease). Geographically, the market is segmented into North America, Europe, Asia-Pacific and LAMEA.

The key market players are Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.

KEY MARKET BENEFITS:

  • In-depth study of the global preimplantation genetic diagnostic market was conducted based on current testing trends of genetic test and based on the preferences for designer babies
  • Potential analysis of opportunities was evaluated for understanding different aspects of preimplantation genetic test that are currently under various phases of clinical trials along with the variants that would gain prominence in the future
  • A deep analysis of key market dynamics that influence the adoption of PGD tests in the forecast period
  • Analysis of volume and vale share analysis of PGD testing at a global and regional level
  • Key market players are profiled and their strategies are analyzed thoroughly for understanding the various technologies adopted by them for development and production of diagnostic tests for PGD testing

KEY MARKET SEGMENT:

By Test Type

  • Chromosomal abnormalities
  • Gender selection
  • X-linked diseases
  • Aneuploidy
  • Single gene disorders
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Key Benefits

  • The report provides an in-depth analysis of the PGD market with current and future estimates to elucidate the investment pockets
  • Current and future trends are outlined to determine the overall attractiveness market and to single out profitable trends to gain a stronger foothold in the market
  • The report provides information regarding key drivers, restraints, and opportunities along with their impact analysis on the PGD market
  • Quantitative analysis of the current market and estimations for 2014–2022 is provided to understand the financial competency of the market
  • Porters Five Forces Model of the industry illustrates the potency of the buyers & suppliers participating in the market
  • Comprehensive analyses of all regions are provided to determine the predominant opportunities in these geographies
  • Key market players of PGD market are analyzed to understand the competitive outline of the global PGD market

Key Market Segments

BY TYPE

  • Chromosomal Abnormalities
  • Aneuploidy
  • X-linked diseases
  • Single Gene Disorder
  • HLA Typing
  • Gender Selection
  • Others

BY GEOGRAPHY:

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments:
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top impacting factor
3.2.2 Top winning strategies
3.2.3 Top investment pockets

3.3 Porters five forces analysis

3.3.1 Low bargaining power of suppliers due to large number of suppliers and moderate switching cost
3.3.2 Moderate bargaining power of buyers due to large number of buyers, high product dependency and moderate switching cost.
3.3.3 Moderate threat of substitutes due to ease of substitution, moderate price war and high brand loyalty
3.3.4 Low threat of new entrants due to presence of dominant players and high investment cost and legal barriers
3.3.5 Presence of numerous players, high growth rate and high economic base increases the competition among rivalries

3.4 Drivers

3.4.1 Effective solution for the healthy embryos
3.4.2 Increasing infertility rate and genetic, hereditary and chromosomal diseases
3.4.3 Innovative and wide range of applications such as development of savior siblings and gender selection among others

3.5 Restraints

3.5.1 Stringent regulations and ethical concerns
3.5.2 High cost incurred and risk involved in PGD

3.6 Opportunities

3.6.1 Increasing adoption of PGD in developing countries

Chapter: 4 WORLD PGD MARKET, BY TEST TYPE

4.1 Introduction
4.2 Chromosomal Abnormalities

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 North America Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.5 Europe Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.6 Asia Pacific Chromosomal Abnormalities Market, Growth (%) 2014-2022
4.2.7 LAMEA Chromosomal Abnormalities Market, Growth (%) 2014-2022

4.3 Aneuploidy

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 North America Aneuploidy Market, Growth (%) 2014-2022
4.3.5 Europe Aneuploidy Market, Growth (%) 2014-2022
4.3.6 Asia Pacific Aneuploidy Market, Growth (%) 2014-2022
4.3.7 LAMEA Aneuploidy Market, Growth (%) 2014-2022

4.4 X-linked Diseases

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 North America X-Linked Diseases Market, Growth (%) 2014-2022
4.4.5 Europe X-Linked Diseases Market, Growth (%) 2014-2022
4.4.6 Asia Pacific X-Linked Diseases Market, Growth (%) 2014-2022
4.4.7 LAMEA X-Linked Diseases Market, Growth (%) 2014-2022

4.5 Single Gene Disorders

4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast
4.5.4 North America Single Gene Disorders Market, Growth (%) 2014-2022
4.5.5 Europe Single Gene Disorders Market, Growth (%) 2014-2022
4.5.6 Asia Pacific Single Gene Disorders Market, Growth (%) 2014-2022
4.5.7 LAMEA Single Gene Disorders Market, Growth (%) 2014-2022

4.6 HLA Typing

4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast
4.6.4 North America HLA Typing Market, Growth (%) 2014-2022
4.6.5 Europe HLA Typing Market, Growth (%) 2014-2022
4.6.6 Asia Pacific HLA Typing Market, Growth (%) 2014-2022
4.6.7 LAMEA HLA Typing Market, Growth (%) 2014-2022

4.7 Gender selection

4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast
4.7.4 North America Gender Selection Market, Growth (%) 2014-2022
4.7.5 Europe Gender Selection Market, Growth (%) 2014-2022
4.7.6 Asia Pacific Gender Selection Market, Growth (%) 2014-2022
4.7.7 LAMEA Gender Selection Market, Growth (%) 2014-2022

4.8 Others PGD Test (Disability and Adult Onset Disease)

4.8.1 Key market trends
4.8.2 Key growth factors and opportunities
4.8.3 Market size and forecast
4.8.4 North America Others PGD Market, Growth (%) 2014-2022
4.8.5 Europe Others PGD Market, Growth (%) 2014-2022
4.8.6 Asia Pacific Others PGD Market, Growth (%) 2014-2022
4.8.7 LAMEA Others PGD Market, Growth (%) 2014-2022

Chapter: 5 WORLD PGD MARKET, BY GEOGRAPHY

5.1 Introduction
5.2 North America

5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast

5.3 Europe

5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast

5.4 Asia Pacific (APAC)

5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast

5.5 LAMEA

5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast

Chapter: 6 COMPANY PROFILE

6.1 Reprogenetics, LLC.

6.1.1 Company Snapshot
6.1.2 Operating business segments
6.1.3 Business performance
6.1.4 Key strategies & developments

6.2 F. Hoffmann-La Roche AG

6.2.1 Company Snapshot
6.2.2 Operating business segments
6.2.3 Business performance
6.2.4 Key strategies & developments

6.3 Genea Limited

6.3.1 Company overview
6.3.2 Company Snapshot
6.3.3 Operating business segments
6.3.4 Business performance
6.3.5 Key strategies & developments

6.4 Illumina, Inc

6.4.1 Company overview
6.4.2 Company Snapshot
6.4.3 Operating business segments
6.4.4 Business performance
6.4.5 Key strategies & developments

6.5 Laboratory Corporation of America Holdings

6.5.1 Company overview
6.5.2 Company Snapshot
6.5.3 Operating business segments
6.5.4 Business performance
6.5.5 Key strategies & developments

6.6 Natera, Inc

6.6.1 Company overview
6.6.2 Company Snapshot
6.6.3 Operating business segments
6.6.4 Business performance
6.6.5 Key strategies & developments

6.7 PerkinElmer, Inc

6.7.1 Company overview
6.7.2 Company Snapshot
6.7.3 Operating business segments
6.7.4 Business performance
6.7.5 Key strategies & developments

6.8 Genesis Genetics Ltd

6.8.1 Company overview
6.8.2 Company Snapshot
6.8.3 Operating business segments
6.8.4 Business performance
6.8.5 Key strategies & developments

6.9 Reproductive Genetics Innovations LLC.

6.9.1 Company overview
6.9.2 Company Snapshot
6.9.3 Operating business segments
6.9.4 Business performance
6.9.5 Key strategies & developments

6.10 Quest Diagnostics Inc.

6.10.1 Company overview
6.10.2 Company Snapshot
6.10.3 Operating business segments
6.10.4 Business performance
6.10.5 Key strategies & developments

List of Finger

FIG. 1 TOP IMPACTING FACTORS
FIG. 2 TOP WINNING STRATEGIES IN THE PGD MARKET (2013-2016)
FIG. 3 TOP WINNING STRATEGIES (%) (2013-2016)
FIG. 4 TOP INVESTMENT POCKETS
FIG. 5 PORTERS FIVE FORCES ANALYSIS OF PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET
FIG. 6 WORLD PGD MARKET BY PRODUCT TYPE, 2015 (PIE CHART OF GLOBAL NUMBERS BY PRODUCT TYPE) REVENUE
FIG. 7 WORLD CHROMOSOMAL ABNORMALITIES MARKET Y-O-Y(%), 2015-2022
FIG. 8 WORLD ANEUPLOIDY MARKET, Y-OY (%), 2015-2022
FIG. 9 WORLD X-LINKED DISEASES MARKET, BY Y-OY (%), 2015-2022
FIG. 10 WORLD PGD SINGLE GENE DISORDERS MARKET, Y-O-Y (%), 2015-2022
FIG. 11 WORLD HLA TYPING MARKET, YOY (%), 2015-2022
FIG. 12 WORLD PGD GENDER SELECTION MARKET, Y-O-Y (%), 2015-2022
FIG. 13 WORLD PGD OTHERS MARKET, Y-OY (%), 2015-2022
FIG. 14 WORLD PGD MARKET BY GEOGRAPHY, 2015 (PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY) REVENUE
FIG. 15 NORTH AMERICA PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
FIG. 16 EUROPE PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
FIG. 17 APAC PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022
FIG. 18 LAMEA PGD MARKET, YEAR ON YEAR GROWTH(%), 2015-2022

List of Tables

TABLE 1 PGD SUCCESS RATES BY THE HUMAN FERTILISATION AND EMBRYOLOGY AUTHORITY (HEFA)
TABLE 2 WORLD CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 3 NORTH AMERICA CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 4 EUROPE CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 5 ASIA PACIFIC CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 6 LAMEA CHROMOSOMAL ABNORMALITIES MARKET, BY REVENUE BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 7 WORLD ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 8 NORTH AMERICA ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 9 EUROPE ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 10 ASIA PACIFIC ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 11 LAMEA ANEUPLOIDY MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 12 WORLD X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 13 NORTH AMERICA X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 14 EUROPE X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 15 ASIA PACIFIC X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 16 LAMEA X-LINKED DISEASES MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 17 WORLD SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%)2014-2022
TABLE 18 NORTH AMERICA SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 19 EUROPE SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 20 ASIA PACIFIC SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 21 LAMEA SINGLE GENE DISORDERS MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 22 WORLD HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 23 NORTH AMERICA HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 24 EUROPE HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 25 ASIA PACIFIC HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 26 LAMEA HLA TYPING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 27 WORLD GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 28 NORTH AMERICA GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 29 EUROPE GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 30 ASIA PACIFIC GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 31 LAMEA GENDER SELECTION MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 32 WORLD OTHERS PGD TESTING MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 33 NORTH AMERICA OTHERS PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 34 EUROPE OTHERS PGD MARKET, ($MILLION), GROWTH (%) 2014-2022
TABLE 35 ASIA PACIFIC OTHERS PGD MARKET, ($MILLION), GROWTH (%) 2014-2022
TABLE 36 LAMEA OTHERS PGD MARKET, ($MILLION), GROWTH (%) 2014-2022
TABLE 37 NORTH AMERICA PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 38 EUROPE PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 39 ASIA PACIFIC PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 40 LAMEA PGD MARKET, BY REVENUE ($MILLION), GROWTH (%) 2014-2022
TABLE 41 REPROGENETICS, LLC.: COMPANY SNAPSHOT
TABLE 42 REPROGENETICS, LLC.: OPERATING SEGMENTS
TABLE 43 REPROGENETICS, LLC.: COMPANY SNAPSHOT
TABLE 44 REPROGENETICS, LLC.: OPERATING SEGMENTS
TABLE 45 GENEA LIMITED.: COMPANY SNAPSHOT
TABLE 46 GENEA LIMITED.: OPERATING SEGMENTS
TABLE 47 ILLUMINA, INC.: COMPANY SNAPSHOT
TABLE 48 ILLUMINA, INC.: OPERATING SEGMENTS
TABLE 49 LABORATORY CORPORATION OF AMERICA HOLDINGS.: COMPANY SNAPSHOT
TABLE 50 LABORATORY CORPORATION OF AMERICA HOLDINGS.: OPERATING SEGMENTS
TABLE 51 NATERA, INC.: COMPANY SNAPSHOT
TABLE 52 NATERA, INC: OPERATING SEGMENTS
TABLE 53 GENESIS GENETICS LTD.: COMPANY SNAPSHOT
TABLE 54 GENESIS GENETICS LTD: OPERATING SEGMENTS
TABLE 55 REPRODUCTIVE GENETICS INNOVATIONS LLC: COMPANY SNAPSHOT
TABLE 56 REPRODUCTIVE GENETICS INNOVATIONS LLC: OPERATING SEGMENTS
TABLE 57 QUEST DIAGNOSTICS INC: COMPANY SNAPSHOT
TABLE 58 QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS

Enquiry Before Buy